ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer
Executive Summary
ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.
You may also be interested in...
In Hep B, Functional Cure Likely Means Two-Part Combination Process
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV
At BioPharm America 2016, ContraVir CEO James Sapirstein explains how CMX157, a lipid formulation of tenofovir (Gilead's Viread for HIV and hepatitis B), could become a backbone agent for advances in combination therapy in hep B.
Start-Up Quarterly Statistics, Q2 2016
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.